Summit Therapeutics (SMMT)
(Delayed Data from NSDQ)
$3.86 USD
+0.31 (8.73%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.86 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Summit Therapeutics PLC falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 186 | 649 | 72 | 66 | 64 |
Receivables | 3 | 8 | 24 | 20 | 14 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 0 | 0 | 1 | 2 | 1 |
Total Current Assets | 190 | 657 | 97 | 88 | 80 |
Net Property & Equipment | 0 | 1 | 1 | 1 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 1 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 2 | 2 | 12 | 14 | 15 |
Deposits & Other Assets | 4 | 1 | 0 | 0 | 0 |
Total Assets | 203 | 664 | 113 | 103 | 96 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 0 | 4 | 6 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 14 | 16 | 7 | 4 | 6 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 20 | 13 | 9 | 3 |
Total Current Liabilities | 20 | 39 | 26 | 20 | 14 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 1 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 100 | 495 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2 | 1 | 3 | 3 | 3 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 125 | 538 | 30 | 23 | 17 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 7 | 2 | 1 | 1 | 1 |
Capital Surplus | 1,066 | 505 | 384 | 293 | 241 |
Retained Earnings | -993 | -378 | -300 | -211 | -158 |
Other Equity | -2 | -2 | -2 | -4 | -5 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 78 | 127 | 83 | 79 | 79 |
Total Liabilities & Shareholder's Equity | 203 | 664 | 113 | 103 | 96 |
Total Common Equity | 78 | 127 | 83 | 79 | 79 |
Shares Outstanding | 700.80 | 211.00 | 97.70 | 82.50 | 67.10 |
Book Value Per Share | 0.11 | 0.60 | 0.85 | 0.96 | 1.18 |
Fiscal Year End for Summit Therapeutics PLC falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 186 | 199 | 215 | 242 |
Receivables | NA | 3 | 6 | 11 | 6 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 0 | 0 | 2 | 0 |
Total Current Assets | NA | 190 | 205 | 228 | 248 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 1 | 1 | 1 | 1 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 2 | 2 | 2 | 2 |
Deposits & Other Assets | NA | 4 | 4 | 0 | 0 |
Total Assets | NA | 203 | 218 | 237 | 255 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 3 | 3 | 1 | 1 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 14 | 7 | 7 | 15 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 1 | 100 | 1 | 0 |
Total Current Liabilities | NA | 20 | 114 | 12 | 17 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 100 | 0 | 100 | 100 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 1 | 2 | 1 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 125 | 119 | 118 | 121 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 7 | 7 | 7 | 7 |
Capital Surplus | NA | 1,066 | 1,051 | 1,050 | 1,049 |
Retained Earnings | NA | -993 | -957 | -935 | -921 |
Other Equity | NA | -2 | -2 | -2 | -1 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 78 | 99 | 120 | 133 |
Total Liabilities & Shareholder's Equity | NA | 203 | 218 | 237 | 255 |
Total Common Equity | 0 | 78 | 99 | 120 | 133 |
Shares Outstanding | 701.70 | 700.80 | 697.80 | 697.60 | 697.60 |
Book Value Per Share | 0.00 | 0.11 | 0.14 | 0.17 | 0.19 |